Study on the efficacy of octreotide acetate for cancer-related bowel obstruction

ABSTRACT: Interventions: Octreotide acetate of 300 ug/day is administered primarily as a continuous subcutaneous infusion using a continuous infusion pump. Dosage is fixed at 300 ug/day until Day 4. In patients extubated by Day 4, dosage is fixed at 300 ug/day until Day 7. Primary outcome(s): Amelioration of abdominal symptoms (subjective parameters) Study Design: Single arm Non-randomized

DISEASE(S): Cancer-related Bowel Obstruction

PROVIDER: 2616030 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR